Modality
Gene Editing
MOA
EZH2i
Target
FGFR
Pathway
STING
FLADPKD
Development Pipeline
Preclinical
~Aug 2013
→ ~Nov 2014
Phase 1
~Feb 2015
→ ~May 2016
Phase 2
~Aug 2016
→ ~Nov 2017
Phase 3
Feb 2018
→ Jan 2031
Phase 3Current
NCT04721318
1,488 pts·ADPKD
2025-08→TBD·Not yet recruiting
NCT06548095
2,798 pts·ADPKD
2019-04→TBD·Not yet recruiting
NCT03324804
790 pts·ADPKD
2018-02→TBD·Not yet recruiting
+1 more trial
6,321 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-01-194.8y awayPh3 Readout· FL
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P3
Not yet…
P3
Not yet…
P3
Not yet…
P3
Not yet…
Catalysts
Ph3 Readout
2031-01-19 · 4.8y away
FL
Not yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04721318 | Phase 3 | ADPKD | Not yet recr... | 1488 | VA |
| NCT06548095 | Phase 3 | ADPKD | Not yet recr... | 2798 | EDSS |
| NCT03324804 | Phase 3 | ADPKD | Not yet recr... | 790 | MRD |
| NCT06380128 | Phase 3 | FL | Not yet recr... | 1245 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ASN-7038 | Ascendis Pharma | Phase 3 | VEGF | |
| Liratinib | Krystal Biotech | NDA/BLA | TIM-3 |